EMA recommendation on biosimilars

21 September 2022

This is the first time that the European Medicines Agency has made a recommendation on biosimilars.

What is it going to change? While the statement has no immediate legal implications, it is predicted to strengthen the position of biosimilars in the EU.

Read more: EMA and HMA support interchangeability of biosimilars – decision regarding substitution remains with the member states